nandrolone undecanoate structure

With simultaneous use of trometamol H and antidiabetic drugs may be a mutual enhancement of the hypoglycemic action (risk of hypoglycaemia), and therefore nandrolone undecanoate structure should avoid simultaneous use of or reduce the dose of the appropriate anti-diabetic drug.

When mixed in a container with other drugs must be considered that the solution of trometamol nandrolone undecanoate structure which may lead to the formation of sludge in the mixture.

If H trometamol mixed in a container with other solutions for parenteral administration opalescence or turbidity is observed, such a solution can not be used combined.

Enhances the effect of narcotic analgesics, aminoglycosides, macrolides (erythromycin, oleandomitsina), chloramphenicol, tricyclic antidepressants. Weaken the effect of indirect anticoagulants (coumarin derivatives), barbiturates, salicylates, while the use of trometamol N.

Contact paravenoznoe drug in space can lead to local tissue necrosis. There is a danger of a tendency to respiratory depression (see. Side effects).

In the process of the drug requires monitoring of blood glucose (risk of hypoglycaemia), ionograms serum bicarbonate concentration, dioxide and acid-base balance of the partial pressure of carbon; carrying out forced diuresis. Use of the drug in infants is possible only if the anticipated benefits exceed the risks.

In order to avoid the development of side effects trometamol should not be administered at high speed. Rapid administration (up to 60 ml / min) is allowed in exceptional nandrolone undecanoate structure cases (for example, to correct acidosis in cardiac arrest).